Dr. Sherman Defines RAI Resistance in Thyroid Cancer

Video

Steven I. Sherman, MD, from the MD Anderson Cancer Center, describes the need to expand the clinical definition of radioactive iodine resistance for patients with thyroid cancer.

Steven I. Sherman, MD, Department Chair, Department of Endocrine Neoplasia and Hormonal Disorders, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, describes the need to expand the clinical definition of radioactive iodine (RAI) resistance for patients with thyroid cancer.

The current definition of RAI resistance includes patients with metastatic thyroid cancers that do not take up RAI but have visible lesions by chest x-ray or CT scan. However, Sherman notes, other important definitions are becoming increasingly recognized, such as lesions that take up RAI but do not respond.

Efforts to expand the clinical definition of RAI resistant thyroid cancer are necessary to identify patients who should receive systemic chemotherapy, Sherman explains.

Related Videos
Christina L. Roland, MD, MS, FACS
Ashish Saxena, MD, PhD
Shruti Tiwari, MD
Scott Kopetz, MD, PhD, FACP
Katharina Hoebel, MD, PhD
Catherine C. Coombs, MD, associate clinical professor, medicine, University of California, Irvine School of Medicine
Naomi Adjei, MD, MPH, MSEd, gynecologic oncology fellow, The University of Texas MD Anderson Cancer Center
John M. Kirkwood, MD, Distinguished Service Professor of Medicine, Sandra and Thomas Usher Professor of Medicine, Dermatology & Translational Science, coleader, Melanoma and Skin Cancer Program, Division of Hematology/Oncology, the University of Pittsburgh
Nizar M. Tannir, MD, FACP, professor; Ransom Horne, Jr. Professor for Cancer Research, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
William B. Pearse, MD